Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Grail

Why Cathie Wood Is Loading Up on This Hot Growth Stock (And Should You?)

This dip in Illumina’s stock could be an attractive opportunity for long-term growth investors.

Barchart

3 Medical Technology Stocks Outperforming in 2025

Three med-tech stocks, TransMedics, Insulet, and GRAIL, are outperforming the market and their sector while forming bullish technical patterns.

MarketBeat

Canyon launches DT Swiss developed suspension fork with 40mm of travel

The new suspension fork, aimed at gravel riding is the culmination of a 4-year project with DT Swiss

Cycling Weekly

From analysis to the latest developments in health,
read the most diverse news in one place.

Canyon launches new suspension fork and Grail RIFT gravel bike: One is promising but the other feels a little mismatched

The brand's new suspension fork has been designed in partnership with DT Swiss and will feature on a Grail gravel bike

Cycling News

5 Momentum Stocks to Buy Now

Amid volatile trade and rising uncertainty, these momentum stocks have shown strong signs of leadership in the first half of 2025.

Kiplinger

3 Under-the-Radar Stocks that Legendary Investor Bill Miller Thinks Are Cheap

He believes these stocks are trading at compelling valuations and could outperform the broader market.

Barchart

Stock Market Today: Dow Jones Up But Nvidia Falls On New China Threat; Cathie Wood Loads Up On This Stock Amid 76% Dive (Live Coverage)

The Dow Jones rose on the stock market today. Treasury Secretary Bessent spoke out on China. Some Warren Buffett stocks are near entries.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Canyon Grail CF SLX 8 AXS review: A gravel race bike that can do it all

The Canyon Grail CF SLX is a rapid gravel race bike that can do everything well

Cycling News

GRAIL Scores Relative Strength Rating Upgrade; Hits Key Benchmark

GRAIL shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 71 to 83.

Investors Business Daily

Stocks Showing Improving Market Leadership: GRAIL Earns 83 RS Rating

GRAIL sees its Relative Strength Rating reach the 80-plus level.

Investors Business Daily

GRAIL: Biotech Stock Targeting $100B Cancer Market

GRAIL is a small biotech stock on the rise big time recently. Its innovative technology gives it the opportunity to capitalize on a massive addressable market.

MarketBeat

One Of IBD's Best Screens Identifies These Four Market Leaders, Including Garmin, Ollie's

Garmin stock, along with Ollie's Bargain Outlet, are among the best stocks to watch on the stock market today.

Investors Business Daily

Canyon Grail CF SL 7 AXS review: a gravel bike of two halves?

The integrated cockpit and aero tubing are somewhat at odds with the Grail's taller stack height

Cycling Weekly

GRAIL Getting Closer To Key Technical Benchmark

A Relative Strength Rating upgrade for GRAIL shows improving technical performance. Will it continue?

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Stocks With Anticipated Strong Earnings Reports

With highly effective drugs and treatment options, chronic disease prevalence, and adoption of technology, the biotech market is thriving. Hence, fundamentally solid biotech stocks Illumina (ILMN), Amgen (AMGN), and Entrada Therapeutics (TRDA) could be ideal with anticipated strong earnings reports. Read more.

Bike Perfect

The Canyon Grail CF SLX 8 AXS is one of the best gravel bikes I have ever tested but I would never buy one

Canyon’s Grail is an optimized gravel racing machine, but is it the pinnacle of gravel tech or death by integration?

Barchart

What You Need to Know Ahead of Illumina's Earnings Release

Illumina is expected to release its second-quarter earnings next month, analysts expect a double-digit earnings dip.

StockNews.com

3 Biopharma Stocks to Buy for Long-Term Growth

With the rising investment in personalized medicine research and development and growing clinical trials, the biopharma industry’s prospects appear promising. Hence, quality biotech stocks, Alnylam Pharmaceuticals (ALNY), Illumina (ILMN), and Gilead Sciences (GILD) with long-term growth might be solid buys. Read more….

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Stocks to Monitor for May Moves

The biotech industry is well poised to flourish, buoyed by its strong emphasis on technology-driven advancements to address complex medical challenges and government funding. Hence, quality biotech stocks Harmony Biosciences Holdings (HRMY), Illumina (ILMN), and Compugen (CGEN) could be ideal watchlist additions for May. Read more….

Golf Monthly

'You Know You’ve Still Got To Go Through Hell To Get There, But If You Can Get It At Stage 2 or 3'... Hall Of Famer Juli Inkster On New Cancer Screening

Are we entering a new worldwide era for cancer screening?

Investors Business Daily

Illumina Ends Its Controversial Grail Battle With A Divestiture; Shares Rise

Illumina stock rose Monday after the company said it would divest its cancer detection outfit, Grail, following a lengthy court battle.

Investors Business Daily

Illumina To Sell Grail After U.S. Antitrust Ruling

Illumina said Sunday it will the sell cancer detection startup after a U.S. appeals court said the $7.1 billion deal violated antitrust laws,